

**Date and Time:** *Tuesday 29 November 2016, 10.00-16.00*

**Glaucoma (GC) Meeting 4**

**Place:** *Boardroom, National Guideline Centre, 180 Great Portland Street, London W1W 5QZ*

**Minutes:** Confirmed

<b>Present:</b>	John Sparrow (JS)	Committee Chair, Consultant Ophthalmologist, Bristol Eye Hospital Honorary Professor of Ophthalmic Health Services Research and Applied Epidemiology, University of Bristol
	Augusto Azuara-Blanco (AAB)	Consultant Ophthalmologist, BHSCT Centre for Public Health Professor of Ophthalmology, Queen's University Belfast
	Helen Doe (HD)	Lay member
	Cecilia Fenerty (CFen)	Consultant Ophthalmologist, Manchester Royal Eye Hospital
	Jane Bell (JB)	Community Optometrist, Community Ophthalmologist Clinic, Dorset
	David Parkins (DP)	Community Optometrist, Kent Assistant Director of Quality for NHS Bexley CCG
	Clare Faulkner (CF)	Directorate Lead Pharmacist Specialist Surgery and Trauma, Oxford University Hospitals NHS Foundation Trust
	Kamal Bishai (KB)	General Practitioner with Specialist Interest in Ophthalmology, West Essex CCG
	Anomika Bedi (AB)	Lay member
	Paul Foster (PF)	Professor of Ophthalmic Epidemiology & Glaucoma Studies, UCL Institute of Ophthalmology, University College London Moorfields Eye Hospital NHS Foundation Trust (honorary consultant)
	Robert Harper (RH)	Optometrist Consultant, Manchester Royal Eye Hospital; Honorary Senior Lecturer, University of Manchester; Honorary Visiting Professor, School of Health Sciences, City University.
	Jane Lynn (JL)	Business Analyst, Resource Impact Assessment Team, NICE
	Anne-Louise Clayton (A-LC)	Editor, NICE
	Natalie Wood (NW)	Project Manager, NGC
	Emma Pottinger (EP)	Research Fellow, NGC
	Hannah Trippier (HT)	Senior Research Fellow, NGC
	Elisabetta Fenu (EF)	Health Economics Lead, NGC
	Jennifer Hill (JH)	Guideline Lead, NGC

**Apologies:**

Kate Ashmore (KA)	Documents Editor/Process Assistant, NGC
-------------------	---

Jill Cobb (JC)  
Ben Doak (BD)  
Rebecca Turner (RT)

Information Specialist, NGC  
Guideline Commissioning Manager, NICE  
Ophthalmology Nurse Consultant, Oxford Eye Hospital

## Notes

1. The Chair welcomed the group to the fourth meeting of this GC. Apologies were received from KA, JC, BD and RT.
2. The Chair reviewed and requested declarations of interest. The Chair declared that in relation to previous declarations recorded in the DOI register, for this meeting, the following action applies.

Date	Item declared	Classification	Action taken
On application (RH)	Received an honorarium from Allergan in the past 12 months for speaking on non-medical glaucoma care at one of their Athena glaucoma education events.	Personal, specific, financial	Declare and participate except in the discussion of pharmacological treatments.

There were also the following new declarations of interest received for this GC meeting.

29.11.2016 (CF)	Newly appointed (Oct 2016) as co-chairperson of UK ophthalmic pharmacists group, who are a registered stakeholder in the glaucoma NICE guideline update. The other co-chair has registered UKOPG as a stakeholder and will act as chair of the group for the purposes of the being a stakeholder in the guideline.	Non-specific, personal, non-financial	Declare and participate
29.11.2016 (PF)	Newly appointed to advise on Google's artificial intelligence on diagnosis and management of eye disease, to take effect in 2017.	Non-specific, personal, financial	Declare and participate
29.11.2016 (AB)	Appointed as specialist member for NHS Digital assisting the dissemination of patient data	Non-specific, personal, non-financial	Declare and participate

3. The minutes and notes from GC3 were reviewed and agreed to be an accurate record of the meeting.
4. A-LC gave a presentation on the role of the NICE editor during the development of the guideline.
5. The committee discussed the draft prognostic evidence reviews.
6. JL gave a presentation on the resource impact assessment and the role of the resource impact assessment team at NICE.
7. EF gave an update on the health economic model.
8. EF gave a presentation on the IOP Network Meta-Analysis.
9. The committee discussed the monitoring intervals recommendations.
10. AOB: Nothing was raised.

**Date of next meeting:** GC5, Monday 16 January 2016, 1000–1600, Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ.